Vinorelbine emulsion regulatory update

Adventrx submitted an NDA to FDA for ANX-530 to treat non-small cell lung cancer (NSCLC). The NDA was submitted under section 505(b)(2) of the Food, Drug and Cosmetic Act, which allows sponsors to ref...